Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling
Rothwell, Dominic G
AffiliationInstitute of Human Genetics, Diagnostic & Research Center for Molecular BioMedicine, Medical University of Graz, 8010 Graz, Austria.
MetadataShow full item record
AbstractMolecular profiling from liquid biopsy, in particular cell-free DNA (cfDNA), represents an attractive alternative to tissue biopsies for the detection of actionable targets and tumor monitoring. In addition to PCR-based assays, Next Generation Sequencing (NGS)-based cfDNA assays are now commercially available and are being increasingly adopted in clinical practice. However, the validity of these products as well as the clinical utility of cfDNA in the management of patients with cancer has yet to be proven. Within framework of the Innovative Medicines Initiative (IMI) program CANCER-ID we evaluated the use of commercially available reference materials designed for ctDNA testing and cfDNA derived from Diagnostic Leukaphereses (DLA) for inter- and intra-assay as well as intra- and inter-laboratory comparisons. In three experimental setups, a broad range of assays including ddPCR, MassARRAY and various NGS-based assays were tested. We demonstrate that both reference materials with predetermined VAFs and DLA samples are extremely useful for the performance assessment of mutation analysis platforms. Moreover, our data indicate a substantial variability of NGS assays with respect to sensitivity and specificity highlighting the importance of extensive validation of the test performance before offering these tests in clinical routine practice. Keywords: assay validation; cell-free DNA; cfDNA; circulating tumor DNA; ctDNA; diagnostic leukaphereses; molecular profiling; mutation analysis; performance assessment; reference material.
CitationWeber S, Spiegl B, Perakis SO, Ulz CM, Abuja PM, Kashofer K, et al. Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling. Cancers (Basel). 2020;12(6).
- Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
- Authors: Liu L, Liu H, Shao D, Liu Z, Wang J, Deng Q, Tang H, Yang H, Zhang Y, Qiu Y, Cui F, Tan M, Zhang P, Li Z, Liu J, Liang W, Wang Y, Peng Z, Wang J, Yang H, Mao M, Kristiansen K, Ye M, He J
- Issue date: 2018 Apr
- Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
- Authors: Al Zoughbi W, Fox J, Beg S, Papp E, Hissong E, Ohara K, Keefer L, Sigouros M, Kane T, Bockelman D, Nichol D, Patchell E, Bareja R, Karandikar A, Alnajar H, Cerqueira G, Guthrie VB, Verner E, Manohar J, Greco N, Wilkes D, Tagawa S, Malbari MS, Holcomb K, Eng KW, Shah M, Altorki NK, Sboner A, Nanus D, Faltas B, Sternberg CN, Simmons J, Houvras Y, Molina AM, Angiuoli S, Elemento O, Mosquera JM
- Issue date: 2021 Jul 19
- Multiplex Cell-Free DNA Reference Materials for Quality Control of Next-Generation Sequencing-Based <i>In Vitro</i> Diagnostic Tests of Colorectal Cancer Tolerance.
- Authors: Liu D, Zhang X, Zhou H, Lin X, Shi D, Shen S, Tian Y, Du B, Zhang H, Wang H, Wang Y, Zhang C
- Issue date: 2018
- Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy).
- Authors: Garcia J, Forestier J, Dusserre E, Wozny AS, Geiguer F, Merle P, Tissot C, Ferraro-Peyret C, Jones FS, Edelstein DL, Cheynet V, Bardel C, Vilchez G, Xu Z, Bringuier PP, Barritault M, Brengle-Pesce K, Guillet M, Chauvenet M, Manship B, Brevet M, Rodriguez-Lafrasse C, Hervieu V, Couraud S, Walter T, Payen L
- Issue date: 2018 Apr 20
- Using circulating cell-free DNA to monitor personalized cancer therapy.
- Authors: Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD
- Issue date: 2017 May